Key Points {#FPar1}
==========

Oral ulcers are one of the key clinical features in juvenile-onset systemic lupus erythematosus (JSLE) patients; however, the terminology remains unclear.There are several oral ulcers in JSLE patients that sometimes go unnoticed, and some ulcers indicate that treatment should be started promptly.Lesional biopsy is required when other oral diseases cannot be excluded, such as oral lichen planus and oral lichenoid contact lesions.

Introduction {#Sec1}
============

Juvenile-onset systemic lupus erythematosus (JSLE) is one of the most common autoimmune diseases in children and has a clinical course ranging from mild, gradual onset to rapid, progressive multi-organ failure \[[@CR1]\]. Approximately 20% of systemic lupus erythematosus (SLE) patients are diagnosed in childhood and adolescence, with a median age of 11--12 years \[[@CR2]--[@CR5]\]. The prevalence of JSLE is high in Asian and African populations, with a female predominance (female to male ratio: 4.7:1--6.2:1) \[[@CR6], [@CR7]\]. JSLE patients usually present with mucocutaneous lesions, renal involvement, central nervous system (CNS) disorders and hematological abnormalities \[[@CR4]\]. The diagnosis of JSLE typically needs four out of 11 criteria based on the revised classification criteria of the American College of Rheumatology (ACR) 1997. However, the new Systemic Lupus International Collaborating Clinics (SLICC) group classification criteria are now widely used in JSLE, and the diagnosis requires at least four out of 17 criteria (including at least one clinical criterion and one immunological criterion), or lupus nephritis with a presence of antinuclear antibody (ANA) or anti-double-stranded DNA (anti-ds DNA) antibodies \[[@CR8], [@CR9]\].

Mucocutaneous manifestations are common signs and symptoms in JSLE at diagnosis, and they are found in approximately 70--75% of JSLE populations worldwide \[[@CR7], [@CR10]--[@CR14]\]. According to the ACR revised criteria, four mucocutaneous features are included, one of which is oral ulcers. The terminology of oral ulcers in these criteria is usually "painless oral or nasopharyngeal ulceration observed by a physician", yet these may be unclear, especially in children \[[@CR15]\]. In the new SLICC group classification criteria, oral ulcers remain included. They are defined more specifically as oral ulcers at palate, buccal mucosa or tongue without other causes (e.g., vasculitis or infection) \[[@CR8]\]. In fact, there are several types of oral ulcers presented in JSLE patients. Moreover, some ulcers (e.g., palatal erythematous ulcers and aphthous ulcers) occur particularly when disease is active. However, other types of ulcers may appear without being related to disease activity and severity \[[@CR16], [@CR17]\].

The mucocutaneous manifestations in JSLE are classified as lupus erythematosus (LE)-specific and LE-nonspecific skin diseases, according to the Gilliam classification of skin lesions associated with LE \[[@CR18]\]. Typical oral ulcers in the ACR criteria and SLICC group classification criteria are LE-specific and most lesions are categorized in chronic cutaneous lupus erythematosus (CCLE), such as oral discoid lupus erythematosus (DLE), whilst others are LE-nonspecific (e.g., aphthous ulcers) \[[@CR10]\].

We searched for literature reviews and studies in the PubMed database using the following key words: "oral/mucosa/mucosal/mucocutaneous" and "lupus/LE/SLE" and "juvenile/child/childhood/children" (until August 1, 2016). All published articles related to the clinical manifestations of oral ulcers in JSLE patients were reviewed.

Epidemiology {#Sec2}
============

Oral ulcers are the second most common mucocutaneous manifestation in JSLE patients after butterfly rash \[[@CR11]\], and they are the most common mucosal sign of JSLE \[[@CR19]\]. The incidence of oral ulcers in JSLE is approximately 11.4--37%, which is significantly higher than in adult SLE \[[@CR4], [@CR5], [@CR20]\]. In adult patients, males have a lower rate of oral ulcers than females, but there are no reports of gender preference in children \[[@CR21]\]. The common oral ulcers in JSLE patients are palatal erythematous ulcers, oral DLE and aphthous ulcers \[[@CR10], [@CR11]\].

Clinical Manifestations {#Sec3}
=======================

Oral mucosa is normally characterized into three types: lining; masticatory and specialized mucosa \[[@CR22], [@CR23]\]. The lining mucosa is nonkeratinized epithelium covering buccal mucosa, labial mucosa, alveolar mucosa, soft palate, ventral tongue and the floor of the mouth \[[@CR24]\], whereas the masticatory mucosa is keratinized mucosa covering gingiva, attached gingiva and hard palate. The dorsal surface of the tongue is covered with specialized mucosa that consists of taste buds and epithelially derived structures called papillae \[[@CR22]--[@CR24]\]. Understanding of these different types of oral mucosa is important for making a diagnosis, as some lesions tend to affect one type of tissue more than the others. The clinical manifestations of oral ulcers in JSLE patients are summarized in Table [1](#Tab1){ref-type="table"} \[[@CR16], [@CR25]--[@CR30]\].Table 1Clinical manifestations of oral ulcers in juvenile-onset systemic lupus erythematosus (JSLE) \[[@CR16], [@CR25]\]ClassificationType of lesionsLocationsKey clinical featuresLE-specific oral ulcersPalatal erythematous ulcerMasticatory mucosa (especially hard palate)Painless, single/multiple erythematous ulcer(s)Oral discoid LELining mucosa (especially buccal mucosa and soft palate)Atrophic plaque with white radiating keratotic striae and painful telangiectasiaHoneycomb plaqueLining and masticatory mucosaChronic, well-circumscribed erythematous plaque with white lacy hyperkeratosisVerrucous LELining mucosaRaised, intense keratotic plaqueLE-nonspecific oral ulcersAphthous ulcerLining mucosaWhite to yellow painful ulcer(s) with erythematous haloLupus cheilitisBuccal lips (especially lower lip)Small or diffuse erythematous and edematous lips, or crusty painful ulcer(s)*LE* lupus erythematosus

Lupus Erythematosus (LE)-Specific Oral Ulcers {#Sec4}
---------------------------------------------

### Palatal Erythematous Ulcers {#Sec5}

A palatal erythematous ulcer is the typical oral ulcer in the ACR criteria, and it is described as a usually painless, single/multiple lesion(s) at masticatory or keratinized mucosa, especially the hard palate (Fig. [1](#Fig1){ref-type="fig"}a). It is an acute sign occurring when disease is active, and sometimes is the first clue of JSLE without skin lesions \[[@CR26]\]. The early lesion may be hemorrhaging before developing into the ulcer \[[@CR10]\]. If the ulcers are coalesced into a large erythematous patch at the hard palate and extend to the soft palate, the early onset of oral DLE should be considered. Palatal erythematous ulcers are sometimes characterized as acute cutaneous lupus erythematosus (ACLE) of LE-specific skin disease in some reports \[[@CR16]\].Fig. 1Oral ulcers in JSLE patients and their differential diagnoses. **a--c** LE-specific oral ulcers: **a** a palatal erythematous ulcer at hard palate; **b** a painful oral discoid LE with well-demarcated radiating white striae at left buccal mucosa; **c** verrucous LE at alveolar ridge. **d--e** LE-nonspecific oral ulcers: **d** multiple aphthous ulcers with erythematous halo at soft palate; **e** extensive erosive lupus cheilitis at both upper and lower lips. **f--h** The differential diagnoses: **f** an oral lichen planus with typical white reticular striae (Wickham striae) at left buccal mucosa and retromolar trigone; **g** an oral lichenoid contact lesion associated with large amalgam filling at left maxillary first molar (*arrow*); **h** clinical improvement 2 weeks after replacement with non-metal restoration. *JSLE* juvenile-onset systemic lupus erythematosus, *LE* lupus erythematosus

### Oral Discoid Lupus Erythematosus {#Sec6}

Oral DLE is a well-defined, atrophic plaque with white radiating keratotic striae and telangiectasia at lining mucosa, especially buccal mucosa and the soft palate (Fig. [1](#Fig1){ref-type="fig"}b) \[[@CR16], [@CR26]\]. JSLE patients often develop an erythematous lesion with painful telangiectasia, and keratotic scaling occurs afterward. The lesion eventually transforms into an atrophic lesion with keratotic border \[[@CR31]\]. The typical oral DLE is composed of (a) white papule/plaque, (b) central erythema, (c) a border zone of irradiating white striae and (d) peripheral telangiectasia \[[@CR27], [@CR28]\]. Although the lesion appears at lining mucosa, the masticatory mucosa may be involved without radiating striae (e.g., hard palate) \[[@CR28]\]. The dental alveolar process is another location that should be carefully inspected, as oral DLE is easily overlooked. Of note, the radiating white striae sometimes resemble the Wickham striae of oral lichen planus (OLP); therefore, a lesional biopsy should be performed if a definite diagnosis is required. Other locations of oral DLE are not common, such as vermilion borders of buccal lips and specialized mucosa (tongue) \[[@CR10], [@CR31]\].

### Honeycomb Plaques {#Sec7}

A honeycomb plaque is described as a chronic, well-circumscribed plaque with white lacy hyperkeratosis and buccal erythema \[[@CR16], [@CR25], [@CR32]\]. The lesion usually occurs at both lining and masticatory tissues, but the lesion at the lining part (e.g., soft palate) is less hyperkeratotic \[[@CR25]\]. Some reports suggest that this lesion is a morphological variant or a late stage of oral DLE \[[@CR18]\]. The incidence of honeycomb plaque in JSLE is very rare.

### Verrucous LE {#Sec8}

Verrucous LE is a rare type of CCLE-specific oral ulcer that has been reported in adult SLE and JSLE \[[@CR16], [@CR33]--[@CR35]\]. The lesion is a raised, intense keratotic plaque normally found at lining mucosa, such as the buccal mucosa and lips. However, the hard palate (e.g., alveolar ridge) may be involved (Fig. [1](#Fig1){ref-type="fig"}c) \[[@CR33]\].

LE-Nonspecific Oral Ulcers {#Sec9}
--------------------------

### Aphthous Ulcers {#Sec10}

An aphthous ulcer is described as a white to yellow painful ulcer with a surrounding red rim. The lesion is usually presented with multiple lesions or in a group, and tends to involve primarily lining tissue: the soft palate, buccal and labial mucosa. Aphthous ulcers are more common in JSLE patients than in adult SLE and usually occur when disease is active \[[@CR36]\]. There are four types of aphthous ulcer, classified as (a) minor ulcers, smaller than 1 cm, usually healing without scar; (b) major ulcers, larger than 1 cm, often healing with scar; (c) herpetiform ulcers, a group of small ulcers (more than ten lesions); and (d) severe ulcers, a continuous minor ulcer lasting months \[[@CR37]\]. In our observations, the most common type of aphthous ulcer in JSLE patients is multiple minor ulcers and less than ten lesions (Fig. [1](#Fig1){ref-type="fig"}d).

### Lupus Cheilitis {#Sec11}

Lupus cheilitis is an inflammation of the buccal lips. The typical lesion is small or diffuse, erythematous and edematous, and may turn into crusty painful ulcers \[[@CR29]\]. Cheilitis often involves the vermilion zone of the lower lip (typical lupus cheilitis) \[[@CR30]\]. As the lesion is found in the sun-exposed area, lupus cheilitis is usually associated with photosensitivity in JSLE patients \[[@CR25]\]. Extensive erosive lupus cheilitis that involves both upper and lower lips has also been reported in JSLE patients and appears in active disease (Fig. [1](#Fig1){ref-type="fig"}e) \[[@CR38]\].

### Other LE-Nonspecific Oral Lesions {#Sec12}

Bullous SLE is a rare clinical manifestation developed by circulating antibodies against type VII collagen at the sub-epidermis. It typically presents with multiple tense bullae at the face, neck and trunk \[[@CR39]\]. Bullous LE at buccal mucosa has been reported in adult SLE and JSLE patients \[[@CR40], [@CR41]\].

Diagnosis {#Sec13}
=========

Clinical evaluation and follow-up is usually sufficient for making a diagnosis of oral ulcers. However, atypical ulcers are sometimes difficult to diagnose, particularly when the patients cannot fulfill the ACR criteria or the new SLICC group classification criteria. In these circumstances, histopathology and immunofluorescence studies are helpful. The histopathology of LE-specific oral ulcers (DLE) shows hyperkeratosis with keratotic plugs. The rete ridge of the mucosa becomes atrophic with deep dermal inflammatory cell infiltration and edematous lamina propria. Positive periodic acid-Schiff staining is found at the juxta-epithelial site in a thick continuous or a patchy pattern \[[@CR42]--[@CR44]\]. In contrast, the histopathology of LE-nonspecific oral ulcers is varied, and no such specific pattern can be identified, as similar findings are also seen in other oral diseases. Direct immunofluorescence of LE-specific oral ulcers shows a band-like deposition of immunoglobulin (IgG, IgM or IgA) at the basement membrane of the lesion \[[@CR45], [@CR46]\], in contrast to pemphigoid diseases, where linear deposits can be seen \[[@CR47]\].

Although clinical features are sufficient for making a diagnosis, there are several diseases with appearances that are similar to the oral ulcers seen in JSLE.

Oral Lichen Planus {#Sec14}
------------------

As mentioned previously, atypical oral DLE may mimic OLP. OLP has multiple clinical appearances, such as reticular, erythematous, plaque-like and erosive types. Oral DLE may resemble the reticular and erythematous types of OLP, which can present as a white lacy patch and erythematous mucosa. However, the most frequent site of involvement in OLP is posterior buccal mucosa (rarely at the palates) (Fig. [1](#Fig1){ref-type="fig"}f) \[[@CR25], [@CR48], [@CR49]\]. Wickham striae are characteristic of OLP, but a lesional biopsy is sometimes necessary when a definite diagnosis cannot be made. The histopathology shows basal cell degeneration damage and dense subepithelial band-like infiltration of T lymphocytes in the subjacent connective tissue \[[@CR50]\]. Direct immunofluorescence is also helpful, as OLP shows positive staining with anti-fibrinogen in the dermoepidermal junction and positive staining with immunoreactive proteins in the colloid bodies \[[@CR16], [@CR51], [@CR52]\].

Oral Lichenoid Contact Lesions {#Sec15}
------------------------------

An oral lichenoid contact lesion (OLCL) is a white patch or plague at the buccal mucosa, and its appearance is similar to oral DLE and OLP \[[@CR27], [@CR53]\] (Fig. [1](#Fig1){ref-type="fig"}g, h). The cause of OLCLs is thought to be a delayed-typed hypersensitivity reaction to a component of dental restorative materials, and use of metallic dental fillings can induce this lesion. OLCLs usually disappear when the metallic dental fillings have been removed \[[@CR27], [@CR53]\].

Leukoplakia {#Sec16}
-----------

Leukoplakia is a homogenous or non-homogenous white plague at the buccal mucosa \[[@CR54]\]. As there are no specific histological findings in this lesion, other causes need to be excluded \[[@CR55]\]. Oral DLE sometimes transforms into a white homogenous plaque when the lesion has persisted for several months. Therefore, it should be considered as one of the differential diagnoses in leukoplakia \[[@CR56]\].

Herpetic Gingivostomatitis {#Sec17}
--------------------------

The typical lesion comprises a group of multiple painful vesicles on an erythematous base at the buccal lips, oral mucosa or tongue, with red and swollen gingiva. A group of multiple ulcers and aphthous ulcers in JSLE are quite similar. However, the important clues of herpetic gingivostomatitis are prodromal symptoms and a history of herpes simplex virus (HSV) infection. A Tzanck smear, demonstrating cytopathic effects of the virus, is useful for diagnosis. The lesion usually spontaneously resolves within 2 weeks \[[@CR57]\]. Therefore, oral ulcers in JSLE should be considered if this lesion still persists beyond 2 weeks.

Management {#Sec18}
==========

Topical anti-inflammatory agents are the treatment of choice for oral ulcers in JSLE \[[@CR58], [@CR59]\]. Topical corticosteroids (e.g., 0.1% triamcinolone oral paste) are one of the most commonly used medications in JSLE patients, and shorten the course and severity of the ulcers. The duration of corticosteroid usage depends on the severity of the symptoms. If the oral lesions are refractory to the treatment, then more potent (e.g., betamethasone or clobetasol in oral preparation) or systemic drugs may be needed \[[@CR58]\]. However, some oral ulcers are very difficult to treat even when high-potency topical corticosteroid is applied, especially palatal erythematous ulcers and oral DLE \[[@CR26]\]. Steroid-sparing agents, such as calcineurin inhibitors (e.g., 0.03 or 0.1% tacrolimus) are also applicable when the side effects of corticosteroids are of concern \[[@CR60], [@CR61]\]. The other route of corticosteroid administration, intra-lesional injection, is rarely used, especially in children, due to pain. Noticeably, systemic corticosteroids are normally prescribed as a first-line drug for treatment in JSLE because most patients develop multiple-organ involvement and these drugs dramatically improve the clinical signs and symptoms, including oral ulcers \[[@CR25], [@CR62]\].

Antimalarial drugs, such as hydroxychloroquine, are usually used as first-line drugs combined with systemic corticosteroids if the patient needs systemic therapy. However, these drugs can be used as a monotherapy in mild cases of JSLE with mucocutaneous manifestations (e.g., malar rash, discoid rash, photosensitivity, including oral ulcers) \[[@CR63], [@CR64]\]. Complete blood counts, eye examination and liver function tests should be monitored, as drug toxicities may occur in children.

Avoiding sun exposure, especially in patients with lupus cheilitis and oral DLE at buccal lips, is recommended, as UV light is an aggravating factor \[[@CR18], [@CR25]\]. Routine wet dressing can soothe the pain, and keeping chapped lips moist using petrolatum ointment or lip balm (with UV protection) is needed.

A regular dental check-up is also recommended in JSLE patients who present with oral ulcers. Good oral hygiene and prevention of secondary bacterial infection with oral rinses containing chlorhexidine should be advised \[[@CR58], [@CR59]\]. An infection should be suspected when the oral ulcers become painful or bleed. Local antibiotics and antifungal agents (e.g., nystatin) should be considered if infection is suspected.

Summary {#Sec19}
=======

Oral ulcers are commonly found in JSLE patients, and the typical lesion is a painless palatal erythematous ulcer at masticatory or keratinized mucosa, especially the hard palate. However, most ulcers including oral DLE and aphthous ulcers in JSLE patients appear at the lining tissue of the oral cavity (e.g., buccal mucosa, soft palate and tongue) and sometimes are unnoticed. Therefore, understanding of their clinical features and locations is very important. Clinical evaluation and follow-up is normally sufficient for making a diagnosis; however, lesional biopsy is needed particularly when other diseases (such as OLP or OLCL) cannot be ruled out. Topical corticosteroids remain the first-line treatment of oral ulcers, but the steroid-sparing agents (calcineurin inhibitors) can also be used in JSLE patients.
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